NCT04944914 is a Phase 3 clinical trial of camrelizumab in Nasopharyngeal Carcinoma, sponsored by Sun Yat-sen University.

Who is sponsoring NCT04944914?

NCT04944914 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04944914?

Interventions in NCT04944914: camrelizumab, stereotactic body radiotherapy.

What condition does NCT04944914 study?

NCT04944914 studies Nasopharyngeal Carcinoma.

Is NCT04944914 still recruiting?

NCT04944914 is currently recruiting now. Last updated 30 June 2021.

Last reviewed 2021-06-30 · How we verify

NCT04944914

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Recruiting now Phase 3 Last updated 30 June 2021

What this trial tests

Phase 3 trial testing camrelizumab in Nasopharyngeal Carcinoma in 188 participants. Currently enrolling.

Timeline

1 June 2021

Primary endpoint
1 June 2024

1 June 2026

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	188
Start date	1 June 2021
Primary completion	1 June 2024
Estimated completion	1 June 2026
Sites	1 location across China

Drugs / interventions tested

camrelizumab — full drug profile →
stereotactic body radiotherapy

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 70, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We intend to compare the efficacy and safety of immunotherapy plus stereotactic body radiotherapy at oligometastatic lesions and immunotherapy alone among patients with oligometastatic nasopharyngeal carcinoma whose primary lesion has been well controlled after radical local-regional treatment through this multicenter randomized phase 3 trial.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, et al · · 2024 · cited 85× · PMID 38254110 · DOI 10.1186/s12943-023-01928-2
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, et al · · 2023 · cited 71× · PMID 37318724 · DOI 10.1007/s11864-023-01101-3
Current status and advances of immunotherapy in nasopharyngeal carcinoma.
Xu JY, Wei XL, Wang YQ, Wang FH. · · 2022 · cited 62× · PMID 35547095 · DOI 10.1177/17588359221096214
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
Siak PY, Heng WS, Teoh SSH, Lwin YY, et al · · 2023 · cited 33× · PMID 37932756 · DOI 10.1186/s12967-023-04673-8
Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives.
Su ZY, Siak PY, Leong CO, Cheah SC. · · 2022 · cited 32× · PMID 35311066 · DOI 10.3389/fonc.2022.840467
Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment.
Jiang J, Ying H. · · 2022 · cited 29× · PMID 35964134 · DOI 10.1186/s13046-022-02457-4
Oligometastatic Head and Neck Cancer: Challenges and Perspectives.
Bahig H, Huang SH, O'Sullivan B. · · 2022 · cited 19× · PMID 36010888 · DOI 10.3390/cancers14163894
Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy.
Turchan WT, Pitroda SP, Weichselbaum RR. · · 2022 · cited 4× · PMID 35303578 · DOI 10.1016/j.neo.2022.100782

Verify or expand the search:

Other trials of camrelizumab

Trials testing the same drug.

NCT07312578 — Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma · Phase 2 · enrolling by invitation
NCT06530082 — A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients Wit · Phase 1 · not yet recruiting
NCT06363825 — A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05624099 — Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. · Phase 2 · recruiting
NCT05789043 — Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma · Phase 3 · recruiting

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04944914 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 30 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04944914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing